Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 2

Results For "Cipla"

129 News Found

Briefs: Cipla and IOL Chemicals and Pharmaceuticals
News | January 21, 2025

Briefs: Cipla and IOL Chemicals and Pharmaceuticals

Mesalazine is used to treat inflammatory bowel disease


Cipla launches India's first inhalable insulin ‘Afrezza’
News | December 19, 2024

Cipla launches India's first inhalable insulin ‘Afrezza’

Afrezza, developed by MannKind Corporation in the USA, offers a needle-free, rapid-acting insulin option for diabetes management


Orchid Pharma and Cipla collaborate to launch antibiotic Cefepime-Enmetazobactam in India
News | June 29, 2024

Orchid Pharma and Cipla collaborate to launch antibiotic Cefepime-Enmetazobactam in India

The launch of Cefepime-Enmetazobactam marks a significant milestone for India's pharmaceutical industry in fight against AMR


Cipla gets 6 observations from USFDA for Goa facility
Drug Approval | June 24, 2024

Cipla gets 6 observations from USFDA for Goa facility

The company will work closely with the USFDA and is committed to address these comprehensively within stipulated time


Cipla EU to invest an additional € 3 million in Ethris
News | June 19, 2024

Cipla EU to invest an additional € 3 million in Ethris

Cipla had earlier invested € 15 million in Ethris in 2022


Cipla receives final approval for the generic version of Somatuline Depot Injection
Drug Approval | May 23, 2024

Cipla receives final approval for the generic version of Somatuline Depot Injection

Cipla's Lanreotide Injection is AP-rated therapeutic equivalent generic version of Somatuline Depot (Lanreotide) Injection


Cipla invests additional Rs. 26 crore in Achira
News | May 16, 2024

Cipla invests additional Rs. 26 crore in Achira

Achira is engaged in development and commercialization of PoC medical test kits in India


Cipla posts Q4 FY24 consolidated PAT at Rs. 939.04 Cr
News | May 11, 2024

Cipla posts Q4 FY24 consolidated PAT at Rs. 939.04 Cr

The company has posted net profit of Rs. 4,121.55 crores for the Financial Year ended March 31, 2024


Cipla receives 1 observation from USFDA for Kurkumbh facility
Drug Approval | May 10, 2024

Cipla receives 1 observation from USFDA for Kurkumbh facility

The company is committed to address this observation comprehensively within stipulated time


Cipla Health strengthens its play in beauty and personal care
News | April 16, 2024

Cipla Health strengthens its play in beauty and personal care

CHL is strengthening its play in the fast-growing beauty and personal care sector